Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Progression02:07

Tumor Progression

6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term outcome of combined liver-kidney transplantation: a single-center experience in China.

Hepato-gastroenterology·2008
Same author

Dolichol biosynthesis and its effects on the unfolded protein response and abiotic stress resistance in Arabidopsis.

The Plant cell·2008
Same author

In vitro interaction of terbinafine with itraconazole and amphotericin B against fungi causing chromoblastomycosis in China.

Medical mycology·2008
Same author

Regulation of autoinducer 2 production and luxS expression in a pathogenic Edwardsiella tarda strain.

Microbiology (Reading, England)·2008
Same author

Ischemic postconditioning inhibits apoptosis after focal cerebral ischemia/reperfusion injury in the rat.

Stroke·2008
Same author

Liver transplantation for hepatocellular carcinoma: Hangzhou experiences.

Transplantation·2008

Related Experiment Video

Updated: Jun 28, 2025

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.7K

Therapeutic progress in relapsed/refractory multiple myeloma.

Qi Chen1,2, Min Zhang1,2, Shan Zheng1,2

  • 1Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, China.

Annals of Hematology
|April 12, 2024
PubMed
Summary

Novel therapies for relapsed/refractory multiple myeloma (MM) show promise. Bispecific antibodies and CAR-T cell therapy targeting BCMA are advancing MM treatment, offering new hope for patients with this incurable cancer.

Keywords:
Multiple myelomaRefractoryRelapseTherapy

More Related Videos

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

6.8K
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.1K

Related Experiment Videos

Last Updated: Jun 28, 2025

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.7K
Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

6.8K
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.1K

Area of Science:

  • Hematology
  • Oncology
  • Immunotherapy

Background:

  • Multiple myeloma (MM) therapeutics have advanced significantly over the last two decades.
  • Current standard first-line MM therapy involves a three-drug regimen plus autologous stem cell transplantation.
  • Despite progress, MM remains incurable, necessitating ongoing research into treatments for relapsed/refractory MM (RRMM).

Purpose of the Study:

  • To review and summarize recent clinical trial results for RRMM therapies over the past five years.
  • To provide a comprehensive overview for clinicians and researchers in the field.
  • To offer insights for future clinical trial design in MM treatment.

Main Methods:

  • Systematic review of clinical trial data for RRMM treatments published within the last five years.
  • Analysis of therapeutic outcomes for novel agents including monoclonal antibodies, bispecific antibodies, and cell therapies.
  • Evaluation of emerging treatment strategies and their efficacy in RRMM.

Main Results:

  • Daratumumab and isatuximab demonstrate continued efficacy as MM treatment options.
  • Emerging antibody drugs (elotuzumab, selinexor) and bispecific antibodies (teclistamab, talquetamab) show promising outcomes in clinical research.
  • Chimeric antigen receptor-T cell (CAR-T) therapy targeting B-cell maturation antigen (BCMA) is highlighted as an optimal approach for MM.

Conclusions:

  • The therapeutic landscape for RRMM is rapidly evolving with novel antibody-based and cell-based strategies.
  • Bispecific antibodies and BCMA-targeted CAR-T therapy represent significant advancements in MM treatment.
  • Continued research and clinical trials are crucial for optimizing RRMM management and improving patient outcomes.